Pancreatic ductal adenocarcinomas (PDAC) are among the most lethal cancers because of their extensive invasion into surrounding tissues and metastasis to distant organs, even during early stages of tumor progression. The poor prognosis for this malignancy also reflects a generally poor response to current therapies. Thus, understanding the biology of these tumors and the mechanisms that promote their invasion and metastasis will provide a basis for developing new methods for diagnosis and treatment. Tumor cells display metabolic alterations that result in enhanced tumor growth or metastasis. Specifically, metabolic reprogramming promotes tumor cell survival under harsh conditions during transit to distant sites and induces proliferation once the tumor cells establish metastatic loci. Aberrant glutamine metabolism is associated with tumor growth in Kras-driven pancreatic cancer. Likewise, our preliminary data demonstrate increased dependence of metastatic lesions on glutamine metabolism. Additionally, we demonstrate that glutamine metabolism regulates responsiveness against gemcitabine by regulating flux through the pyrimidine biosynthesis pathway. We identify SIRT5 as a key negative regulator of glutamine metabolism that diminishes glutamine uptake and dependence in pancreatic cancer cells. SIRT5 diminishes tumor growth and metastasis in orthotopic models. We also observe that SIRT5 negatively regulates the expression of Elk-3, which promotes glutamine metabolism, pancreatic cancer cell survival, and invasiveness. Of particular significance to the proposal, ELK3 is significantly overexpressed by advanced primary and metastatic pancreatic tumor lesions, and hence ELK3- induced metabolic reprogramming is expected to be a target for suppressing pancreatic tumor progression and metastasis. Our long-term goal is to determine the molecular basis of SIRT5/ELK3-mediated metabolic alterations that facilitate progression and metastasis in pancreatic cancer. Here, we hypothesize that SIRT5/ELK3- mediated regulation of glutamine metabolism contributes to tumor progression, metastasis, and chemoresistance in PDAC. Furthermore, we hypothesize that targeting glutamine metabolism can provide a therapeutic strategy to combat tumor progression, metastasis, and chemoresistance in PDAC. Here, we propose to characterize the metabolic phenotype in SIRT5-deficient pancreatic tumor models (Aim 1) and investigate if Elk3-mediated transcriptional and metabolic reprogramming contributes to SIRT5-mediated metabolic phenotype (Aim 2). Furthermore, we propose to elucidate the role of ELK3 in regulating tumor progression, metastasis, and gemcitabine resistance in PDAC (Aim 3). These studies will elucidate the metabolic aspects of SIRT5/ELK3-mediated tumor progression and metastasis and are strongly expected to uncover additional therapeutic strategies for the treatment of pancreatic cancer.
The exact nature of metabolic reprogramming that contributes to metastasis and chemotherapy resistance is not fully understood. This proposal aims to investigate the mechanistic role and therapeutic potential of targeting glutamine metabolism in regulating metastasis and chemotherapeutic resistance in PDAC. Our studies will provide insights into the mechanism of SIRT5/ELK3-mediated metabolic alterations that facilitate cancer progression and will lead to new clinical treatments for human pancreatic cancer.
|Murthy, Divya; Attri, Kuldeep S; Singh, Pankaj K (2018) Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. Front Physiol 9:335|
|Goodwin, Justin; Choi, Hyunsung; Hsieh, Meng-Hsiung et al. (2018) Targeting Hypoxia-Inducible Factor-1?/Pyruvate Dehydrogenase Kinase 1 Axis by Dichloroacetate Suppresses Bleomycin-induced Pulmonary Fibrosis. Am J Respir Cell Mol Biol 58:216-231|
|Attri, Kuldeep S; Mehla, Kamiya; Shukla, Surendra K et al. (2018) Microscale Gene Expression Analysis of Tumor-Associated Macrophages. Sci Rep 8:2408|
|Gunda, Venugopal; Souchek, Joshua; Abrego, Jaime et al. (2017) MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer. Clin Cancer Res 23:5881-5891|
|Shukla, Surendra K; Purohit, Vinee; Mehla, Kamiya et al. (2017) MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell 32:71-87.e7|
|Souchek, Joshua J; Davis, Amanda L; Hill, Tanner K et al. (2017) Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells. Mol Cancer Ther 16:1819-1830|
|Tadros, Saber; Shukla, Surendra K; King, Ryan J et al. (2017) De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer. Cancer Res 77:5503-5517|
|Abrego, Jaime; Gunda, Venugopal; Vernucci, Enza et al. (2017) GOT1-mediated anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells. Cancer Lett 400:37-46|
|Goode, Gennifer; Gunda, Venugopal; Chaika, Nina V et al. (2017) MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer. PLoS One 12:e0176820|
|Gebregiworgis, Teklab; Purohit, Vinee; Shukla, Surendra K et al. (2017) Glucose Limitation Alters Glutamine Metabolism in MUC1-Overexpressing Pancreatic Cancer Cells. J Proteome Res 16:3536-3546|
Showing the most recent 10 out of 12 publications